Pasar al contenido principal

VALIDACION DE BIOMARCADORES CANDIDATOS PARA EL DIAGNOSTICO Y LA PROGRESION DE LA ESCLEROSIS LATERAL AMIOTROFICA Y ESTUDIO DE LAS VIAS FISIOPATOGENICAS IMPLICADAS

PI19/01543

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Profiling TREM2 expression in amyotrophic lateral sclerosis

  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Vicuña-Urriza, J.
  • Blanco-Luquin, I.
  • Macias, M.
  • Martinez-Merino, L.
  • Roldán, M.
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Pagola-Lorz, Inma
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Zelaya, V.
  • Mendioroz, Maite|||0000-0002-4179-5781
There is growing evidence of the contribution of neuroinflammation, and in particular microglia, in the pathogenesis of amyotrophic lateral sclerosis (ALS). TREM2 gene plays a crucial role in shaping microglia in neurodegenerative conditions. To deepen the understanding of TREM2 in ALS and investigate the performance of TREM2 as a biomarker, we profiled TREM2 expression levels in spinal cord, cerebrospinal fluid and blood of patients with sporadic ALS. We also wanted to investigate whether the combined measurement of sTREM2 in fluids could improve the diagnostic yield of total and phosphorylated TDP-43 levels. We performed a case-control study to profile overall and transcript-specific TREM2 mRNA levels by RT-qPCR and protein expression levels by Western-blot in postmortem specimens of spinal cord from ALS patients and controls. In parallel, we measured soluble TREM2 (sTREM2) protein levels and full length and phosphorylated TDP-43 (tTDP-43 and pTDP-43) by ELISA in CSF and serum from ALS patients vs healthy controls. Patients were prospectively recruited from an ALS unit of a tertiary hospital and fulfilled El Escorial revised criteria. After bivariate analysis, a logistic regression model was developed to identify adjusted estimates of the association of sTREM2 levels in CSF and serum with ALS status. Overall and transcript-specific TREM2 mRNA were upregulated in the spinal cord of ALS patients (n = 21) compared to controls (n = 19). Similar changes were observed in TREM2 protein levels (p < 0.01) in spinal cord of ALS patients vs healthy controls. We also detected significantly higher sTREM2 levels in CSF (p-value < 0.01) of ALS patients (n = 46) vs controls (n = 46) and serum (p-value < 0.001) of ALS patients (n = 100) vs controls (n = 100). In a logistic regression model, both CSF and serum sTREM2 remained independently associated with ALS status with OR = 3.41 (CI 95 %=1.34-8.66) (p-value < 0.05) and OR = 3.38 (CI 95 %: 1.86-6.16) (p-value < 0.001), respectively. We also observed that pTDP-43 levels in CSF is an independent predictor of ALS (p-value < 0.05). Our results support the role of TREM2 in ALS pathophysiology and demonstrates that the three TREM2 transcripts are deregulated in ALS in postmortem human specimens of spinal cord. We hypothesise about the possible influence of systemic-peripheral inflammation in the disease. Finally, we conclude that pTDP-43 levels in CSF could be a biomarker of ALS, and sTREM2 measurement in CSF and blood emerge as potential non-invasive biomarker in ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell RNA sequencing highlights the role of distinct natural killer subsets in sporadic amyotrophic lateral sclerosis

  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Muñoz, Laia|||0000-0003-0578-3094
  • Aumatell Escabias, Joaquim
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Lleó, Alberto|||0000-0002-2568-5478
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Fortea, Juan|||0000-0002-1340-638X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Dols Icardo, Oriol|||0000-0003-2656-8748
Neuroinflammation plays a major role in amyotrophic lateral sclerosis (ALS), and cumulative evidence suggests that systemic inflammation and the infiltration of immune cells into the brain contribute to this process. However, no study has investigated the role of peripheral blood immune cells in ALS pathophysiology using single-cell RNA sequencing (scRNAseq). We aimed to characterize immune cells from blood and identify ALS-related immune alterations at single-cell resolution. For this purpose, peripheral blood mononuclear cells (PBMC) were isolated from 14 ALS patients and 14 cognitively unimpaired healthy individuals (HC), matched by age and gender, and cryopreserved until library preparation and scRNAseq. We analyzed differences in the proportions of PBMC, gene expression, and cell-cell communication patterns between ALS patients and HC, as well as their association with plasma neurofilament light (NfL) concentrations, a surrogate biomarker for neurodegeneration. Flow cytometry was used to validate alterations in cell type proportions. We identified the expansion of CD56 dim natural killer (NK) cells in ALS (fold change = 2; adj. p -value = 0.0051), mainly driven by a specific subpopulation, NK_2 cells (fold change = 3.12; adj. p -value = 0.0001), which represent a mature and cytotoxic CD56 dim NK subset. Our results revealed extensive gene expression alterations in NK_2 cells, pointing towards the activation of immune response (adj. p -value = 9.2 × 10 - 11) and the regulation of lymphocyte proliferation (adj. p -value = 6.46 × 10 - 6). We also identified gene expression changes in other immune cells, such as classical monocytes, and distinct CD8 + effector memory T cells which suggested enhanced antigen presentation via major histocompatibility class-II (adj. p -value = 1.23 × 10 - 8) in ALS. The inference of cell-cell communication patterns demonstrated that the interaction between HLA-E and CD94:NKG2C from different lymphocytes to NK_2 cells is unique to ALS blood compared to HC. Finally, regression analysis revealed that the proportion of CD56 bright NK cells along with the ALSFRS-r, disease duration, and gender, explained up to 76.4% of the variance in plasma NfL levels. Our results reveal a signature of relevant changes occurring in peripheral blood immune cells in ALS and underscore alterations in the proportion, gene expression, and signaling patterns of a cytotoxic and terminally differentiated CD56 dim NK subpopulation (NK_2), as well as a possible role of CD56 bright NK cells in neurodegeneration. The online version contains supplementary material available at 10.1186/s12974-025-03347-0.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Characterizing SOD1 mutations in Spain. The impact of genotype, age, and sex in the natural history of the disease

  • Vázquez-Costa, Juan F.
  • Borrego-Hernández, Daniel
  • Paradas, Carmen
  • Gómez-Caravaca, María Teresa
  • Rojas-García, Ricardo
  • Varona, Luis
  • Povedano, Mónica
  • García-Sobrino, Tania
  • Jericó Pascual, Ivonne
  • Gutiérrez, Antonio
  • Riancho, Javier
  • Turón-Sans, Janina
  • Assialioui, Abdelilah
  • Pérez-Tur, Jordi
  • Sevilla, Teresa
  • Esteban Pérez, Jesús
  • García-Redondo, Alberto
11 páginas, 3 figuras, 2 tablas, Introduction: The aim of this study is to describe the frequency and distribution of SOD1 mutations in Spain, and to explore those factors contributing to their phenotype and prognosis. Methods: Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers. Results: In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all 5 exons of SOD1, including 7 novel mutations. 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. Its frequency varied considerably between regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp(Estimate) = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (HR = 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated to faster disease progression (exp(Estimate) = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs 301 months). Conclusions: These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments., This study has received funding from: Instituto de Salud Carlos III (21/00737 PI J.F.V.C., 19/01178 PI T.S., PI 19/01543 to R.R.), cofunded by European Regional Development Fund (‘A way to make Europe’); STOPELA (2017/0653); I + D biomedicina 2017 from Comunidad de Madrid ‘ELA-Madrid’ (B2017/BMD-3813 to A.G.-R.); estrategias frente a Enfermedades Neurodegenerativas Ministerio de Sanidad – Comunidad de Madrid B.O.C.M. Num. 142 - Lunes 17 de junio de 2019 - Pág. 10 ‘Estudio genético de la población con ELA de la Comunidad de Madrid’ to A.G.-R. The Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) are initiatives from the ISCIII. J.F.V.C., T.S., C.P., M.P., R.R.-G., J.T.S. and R.J.M. are members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis, New Insights From Biomarker Studies

  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) lie at opposing ends of a clinical, genetic, and neuropathological continuum. In the last decade, it has become clear that cognitive and behavioral changes in patients with ALS are more frequent than previously recognized. Significantly, these non-motor features can impact the diagnosis, prognosis, and management of ALS. Partially overlapping neuropathological staging systems have been proposed to describe the distribution of TAR DNA-binding protein 43 (TDP-43) aggregates outside the corticospinal tract. However, the relationship between TDP-43 inclusions and neurodegeneration is not absolute and other pathophysiological processes, such as neuroinflammation (with a prominent role of microglia), cortical hyperexcitability, and synaptic dysfunction also play a central role in ALS pathophysiology. In the last decade, imaging and biofluid biomarker studies have revealed important insights into the pathophysiological underpinnings of extra-motor neurodegeneration in the ALS-FTLD continuum. In this review, we first summarize the clinical and pathophysiological correlates of extra-motor neurodegeneration in ALS. Next, we discuss the diagnostic and prognostic value of biomarkers in ALS and their potential to characterize extra-motor neurodegeneration. Finally, we debate about how biomarkers could improve the diagnosis and classification of ALS. Emerging imaging biomarkers of extra-motor neurodegeneration that enable the monitoring of disease progression are particularly promising. In addition, a growing arsenal of biofluid biomarkers linked to neurodegeneration and neuroinflammation are improving the diagnostic accuracy and identification of patients with a faster progression rate. The development and validation of biomarkers that detect the pathological aggregates of TDP-43 in vivo are notably expected to further elucidate the pathophysiological underpinnings of extra-motor neurodegeneration in ALS. Novel biomarkers tracking the different aspects of ALS pathophysiology are paving the way to precision medicine approaches in the ALS-FTLD continuum. These are essential steps to improve the diagnosis and staging of ALS and the design of clinical trials testing novel disease-modifying treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis

  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Illa, Isabel|||0000-0002-2186-2684
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease for which the pathophysiological mechanisms of motor neuron loss are not precisely clarified. Environmental and epigenetic mechanisms such as microRNAs (miRNAs) could have a role in disease progression. We studied the expression pattern of miRNAs in ALS serum from 60 patients and 29 healthy controls. We also analyzed how deregulated miRNAs found in serum affected cellular pathways such as apoptosis, autophagy and mitochondrial physiology in SH-SY5Y cells. We found that miR-335-5p was downregulated in ALS serum. SH-SY5Y cells were transfected with a specific inhibitor of miR-335-5p and showed abnormal mitochondrial morphology, with an increment of reactive species of oxygen and superoxide dismutase activity. Pro-apoptotic caspases-3 and 7 also showed an increased activity in transfected cells. The downregulation of miR-335-5p, which has an effect on mitophagy, autophagy and apoptosis in SH-SY5Y neuronal cells could have a role in the motor neuron loss observed in ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis

  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Pagola-Lorz, Inma
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Querol, Luis|||0000-0002-4289-8264
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of unknown etiology and poorly understood pathophysiology. There is no specific biomarker either for diagnosis or prognosis. The aim of our study was to investigate differentially expressed proteins in the CSF and serum from patients with ALS to determine their role in the disease process and evaluate their utility as diagnostic or prognostic biomarkers. We performed mass spectrometry in the CSF from 3 patients with ALS and 3 healthy controls (HCs). The results were compared with motor cortex dysregulated transcripts obtained from 11patients with sporadic ALS and 8 HCs. Candidate proteins were tested using ELISA in the serum of 123 patients with ALS, 30 patients with Alzheimer disease (AD), 28 patients with frontotemporal dementia (FTD), and 102 HCs. Patients with ALS, AD, and FTD were prospectively recruited from January 2003 to December 2020. A group of age-matched HCs was randomly selected from the Sant Pau Initiative on Neurodegeneration cohort of the Sant Pau Memory Unit. Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and osteopontin (Spp1) were differentially expressed in the CSF and the motor cortex transcriptome of patients with ALS compared with that in HCs (p < 0.05). NOD2 and Spp1 levels were significantly higher in sera from patients with ALS than in HCs (p < 0.001). Receiver operating characteristic analysis showed an area under the curve of 0.63 for NOD2 and 0.81 for Spp1. NOD2 levels were significantly lower in patients with AD and FTD than in patients with ALS (p < 0.0001), but we found no significant differences in Spp1 levels between patients with ALS, AD (p = 0.51), and FTD (p = 0.42). We found a negative correlation between Spp1 levels and ALS functional rating scale (r = -0.24, p = 0.009). Our discovery-based approach identified NOD2 as a novel biomarker in ALS and adds evidence to the contribution of Spp1 in the disease process. Both proteins are involved in innate immunity and autophagy and are increased in the serum from patients with ALS. Our data support a relevant role of neuroinflammation in the pathophysiology of the disease and may identify targets for disease-modifying treatments in ALS. Further longitudinal studies should investigate the diagnostic and prognostic value of NOD2 and Spp1 in clinical practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Motor neuron involvement expands the neuropathological phenotype of late-onset ataxia in RFC1 mutation (CANVAS)

  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
Neuropathological features in brainstem, cerebellum and spinal cord. In addition to cerebellar, vestibullar nuclei and spinal cord posterior columns involvement, a moderate reduction of motor neurons in hypoglossal nucleus and anterior horn of the thoracic spinal cord was present.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis

  • Esteller Gauxax, Diana|||0000-0003-0975-3052
  • Morrow, Jasper
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Bisogni, Giulia|||0000-0001-7314-3393
  • Cateruccia, Michela
  • Monforte, Mauro|||0000-0002-4327-6969
  • Tasca, Giorgio|||0000-0003-0849-9144
  • Alangary, Aljwhara
  • Marini-Bettolo, Chiara|||0000-0003-3795-6017
  • Sabatelli, Mario|||0000-0001-6635-4985
  • Laura, Matilde
  • Ramdharry, Gita
  • Bolano-Diaz, C.
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Töpf, Ana
  • Guglieri, Michela|||0000-0002-8455-0637
  • Rossor, Alexander
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Bertini, Enrico
  • Straub, Volker|||0000-0001-9046-3540
  • Reilly, Mary M.
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Distal motor neuropathies (dHMN) are an heterogenous group of diseases characterized by progressive muscle weakness affecting predominantly the distal muscles of the lower and upper limbs. Our aim was to study the imaging features and pattern of muscle involvement in muscle magnetic resonance imaging (MRI) in dHMN patients of suspected genetic origin (dHMN). We conducted a retrospective study collecting clinical, genetic and muscle imaging data. Muscle MRI included T1-weighted and T2 weighted Short Tau Inversion Recovery images (STIR-T2w) sequences. Muscle replacement by fat was quantified using the Mercuri score. Identification of selective patterns of involvement was performed using hierarchical clustering. Eighty-four patients with diagnosis of dHMN were studied. Fat replacement was predominant in the distal lower leg muscles (82/84 cases), although also affected thigh and pelvis muscles. Asymmetric involvement was present in 29% of patients. The superficial posterior compartment of the leg, including the soleus and gastrocnemius muscles, was the most affected area (77/84). We observed a reticular pattern of fatty replacement progressing towards what is commonly known as "muscle islands" in 79.8%. Hyperintensities in STIR-T2w were observed in 78.6% patients mainly in distal leg muscles. Besides features common to all individuals, we identified and describe a pattern of muscle fat replacement characteristic of BICD2, HSPB1 and DYNC1H1 patients. We conclude that muscle MRI of patients with suspected dHMN reveals common features helpful in diagnosis process.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of a pathogenic mutation in ARPP21 in patients with amyotrophic lateral sclerosis

  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Blasco-Martínez, Olga
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • López Pérez, Maria Angeles
  • Bernal, Sara|||0000-0003-4427-0574
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Cusco, Ivon|||0000-0003-2104-9332
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Cabezas-Torres, Manuel|||0009-0009-4547-2152
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Llansó, Laura|||0000-0003-4950-7657
  • Pagola-Lorz, Maria Inmaculada|||0000-0002-5723-1374
  • Torné, Laura
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Muñoz, Laia|||0000-0003-0578-3094
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
Background and objective: Between 5% and 10% of amyotrophic lateral sclerosis (ALS) cases have a family history of the disease, 30% of which do not have an identifiable underlying genetic cause after a comprehensive study of the known ALS-related genes. Based on a significantly increased incidence of ALS in a small geographical region from Spain, the aim of this work was to identify novel ALS-related genes in ALS cases with negative genetic testing. Methods: We detected an increased incidence of both sporadic and, especially, familial ALS cases in a small region from Spain compared with available demographic and epidemiological data. We performed whole genome sequencing in a group of 12 patients with ALS (5 of them familial) from this unique area. We expanded the study to include affected family members and additional cases from a wider surrounding region. Results: We identified a shared missense mutation (c.1586C.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinicopathological correlates in the frontotemporal lobar degeneration-motor neuron disease spectrum

  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Gascon Bayarri, Jordi|||0000-0002-9422-937X
  • Rubio, Miguel Ángel|||0000-0003-0735-6854
  • Povedano, Mónica
  • Gamez, Josep|||0000-0003-3127-7486
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Juntas Morales, Raúl|||0000-0003-2205-1741
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Marquié, Marta|||0000-0002-0660-0950
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Bernal, Sara|||0000-0003-4427-0574
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease (MND) that shares a common clinical, genetic and pathologic spectrum with frontotemporal dementia (FTD). It is highly heterogeneous in its presentation and features. Up to 50% of patients with MND develop cognitive-behavioural symptoms during the course of the disease, meeting criteria for FTD in 10%-15% of cases. In the absence of a precise biomarker, neuropathology is still a valuable tool to understand disease nosology, reach a definite diagnostic confirmation and help define specific subgroups of patients with common phenotypic, genetic and biomarker profiles. However, few neuropathological series have been published, and the frequency of frontotemporal lobar degeneration (FTLD) in MND is difficult to estimate. In this work we describe a large clinicopathological series of MND patients, analysing the frequency of concurrent FTLD changes and trying to define specific subgroups of patients based on their clinical, genetic and pathological characteristics. We performed an observational, retrospective, multicentre case study. We included all cases meeting neuropathological criteria for MND from the Neurological Tissue Bank of the FRCB-IDIBAPS-Hospital Clínic Barcelona Biobank between 1994 and 2022, regardless of their last clinical diagnosis. While brain donation is encouraged in all patients, it is performed in very few, and representativeness of the cohort might not be precise for all patients with MND. We retrospectively reviewed clinical and neuropathological data and describe the main clinical, genetic and pathogenic features, comparing neuropathologic groups between MND with and without FTLD changes and aiming to define specific subgroups. We included brain samples from 124 patients, 44 of whom (35.5%) had FTLD neuropathologic features (i.e. FTLD-MND). Pathologic TDP-43 aggregates were present in 93.6% of the cohort and were more extensive (higher Brettschneider stage) in those with concurrent FTLD (P < 0.001). Motor symptom onset was more frequent in the bulbar region in FTLD-MND cases than in those with isolated MND (P = 0.023), with no differences in survival. We observed a better clinicopathological correlation in the MND group than in the FTLD-MND group (93.8% versus 61.4%; P < 0.001). Pathogenic genetic variants were more common in the FTLD-MND group, especially C9orf72. We describe a frequency of FTLD of 35.5% in our series of neuropathologically confirmed cases of MND. The FTLD-MND spectrum is highly heterogeneous in all aspects, especially in patients with FTLD, in whom it is particularly difficult to define specific subgroups. In the absence of definite biomarkers, neuropathology remains a valuable tool for a definite diagnosis, increasing our knowledge in disease nosology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterizing SOD1 mutations in Spain, The impact of genotype, age and sex in the natural history of the disease

  • Vázquez-Costa, Juan F.|||0000-0002-3043-7938
  • Borrego-Hernández, Daniel
  • Paradas, Carmen|||0000-0002-6917-2236
  • Gómez-Caravaca, María Teresa
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Varona, Luis|||0000-0001-6256-5478
  • Povedano, Mónica
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Riancho, Javier|||0000-0001-7929-1055
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Assialioui, Abdelilah|||0000-0002-1381-9600
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Sevilla, Teresa|||0000-0003-4716-2667
  • Esteban Pérez, Jordi
  • García-Redondo, Alberto
  • Andrés López, Alberto
  • Calabria, M. Dolores
  • Díaz-Marín, Carmen
  • Fages Caravaca, Eva
  • Galán Dávila, Lucía
  • García Martínez, Alberto
  • Gimenez-Muñoz, Álvaro
  • Guerrero Sola, Antonio
  • Mascías Cadavid, Javier
  • Mora Pardina, Jesús S.
  • Muñoz-Blanco, José Luis
  • Juntas Morales, Raúl|||0000-0003-2205-1741
  • Morgado, Yolanda
  • Pardo, Julio|||0000-0001-8807-1310
  • Valladares, Amador
  • Vilar-Ventura, Rosa María
The aim of this study was to describe the frequency and distribution of SOD1 mutations in Spain, and to explore factors contributing to their phenotype and prognosis. Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers. In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all five exons of SOD1, including seven novel mutations. A total of 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. The frequency of this mutation varied considerably among regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp[Estimate] = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (hazard ratio 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated with faster disease progression (exp[Estimate] = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs. 301 months). These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments.